Especially, EGFR is more highly overexpressed (80–90%) in head and neck cancers (HNCs) than in any other cancer types, and this overexpression is strongly associated with a poor prognosis of HNC patients [10], suggesting that EGFR-targeted therapy may be a significant interest in HNC. Here, EGFR is linked to head and neck cancer.